



ESC Declaration of Interest Report

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

The ESC reviews relationships with industry and encourages transparency and ethical integrity.

It is mandatory for all experts involved in Guidelines development to comply with the ESC Declaration and Management of Conflict of Interest Policy. Under this policy, they are required to submit yearly Declaration of Interest (DOI) forms during the writing and reviewing phases of the Guidelines.

All DOIs are assessed prior to work commencing, and the ESC may decide to exclude any expert from a Guidelines activity based on the exclusion criteria as defined in the [ESC Declaration and Management of Conflict of Interest Policy](#) and accompanying [2012 ESC Policy statement : Relations between professional medical associations and the health-care industry, concerning scientific communication and continuing medical education](#).

Any form of the following characteristics may disqualify an individual from serving on a Guidelines committee, if related to the guideline topic:

- Part-time employment or salary
- Stock ownership
- Holding of a patent which generates revenues
- Receipt of royalties for intellectual property

The following additional characteristics may also disqualify an individual for the positions of CPG Chairperson, Guidelines Task Force Chairperson and Guidelines Review Coordinator:

- Personally received payments from healthcare industry of 10,000€ or higher per year.
- Payments from healthcare industry of 10,000€ or higher per year, made to one's institution/hospital or to other legal bodies which have generated a direct or indirect personal benefit/asset.

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Barbato Emanuele	2018 Financial Declaration Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry. - Boston Scientific : Speaker fees - Abbott Vascular : Speaker fees
	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself - GE Healthcare : Coronary physiology - Abbott Vascular : Coronary physiology - Boston Scientific : Treatment of calcified coronary lesions
Barthelemy Olivier	2018 Nothing to be declared
	2019 Financial Declaration Travel and meeting support from healthcare industry, independent of the above activities. For yourself - Amgen : Cardiology (ESC congress) - Bayer Healthcare : CTO (MLCTO meeting) - Boston Scientific : CTO (workshop) - Cardinal health : PCI / TAVI (High Tech meeting)

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Bauersachs Johann	<p>2018</p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : ACS, Afib - Orion : Acute Heart Failure - Abiomed : acute heart failure - Boehringer-Ingelheim : Afib, Diabetes mellitus, Heart Failure - Bayer : Afib, heart failure - Bristol Myers Squibb : Afib, heart failure - Merck Sharp & Dohme : CAD, Hypercholesterolemia, heart failure - Abbott : Heart Failure - Medtronic : Heart Failure - Servier : Heart Failure - CVRx : Heart Failure - Pfizer : Heart Failure, Afib - Biotronik : Heart Failure, CAD - Vifor International : heart failure, hyperkalemia - Astrazeneca : heart failure, hyperkalemia - Novartis : Hypertension, Heart Failure <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> - Zoll Medical : Arrhythmia - Medtronic : CAD, heart failure

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Bauersachs Johann	2018 <ul style="list-style-type: none"> - Abiomed : cardiogenic shock - Vifor International : Heart failure - CVRx : Heart Failure - Bayer : heart failure, CAD
	2019 <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Abiomed : acute heart failure - Daiichi Sankyo : Afib - Pfizer : Afib, Amyloidosis - Boehringer-Ingelheim : Afib, Diabetes mellitus, Heart Failure - Bayer : Afib, heart failure - Bristol Myers Squibb : Afib, heart failure - Merck Sharp & Dohme : CAD, Hypercholesterolemia, heart failure - Abbott : Heart Failure - Medtronic : Heart Failure - Novartis : Heart Failure - Servier : Heart Failure - CVRx : Heart Failure - Vifor International : heart failure, hyperkalemia - Astrazeneca : heart failure, hyperkalemia <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> - Zoll Medical : Arrhythmia

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Bauersachs Johann	2019 <ul style="list-style-type: none"> - Abiomed : cardiogenic shock - Vifor International : Heart failure - CVRx : Heart Failure
Bhatt Deepak	2018 <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Tobesoft : Board of Directors - WebMD : CME steering committees, CME programs - Population Research Institute, McMaster, Hamilton, Canada : COMPASS Trial Steering Committee; DSMBs - Mayo Clinic : DSMB - Mount Sinai : DSMB - Cleveland Clinic Research Foundation : DSMB member - Baim Clinical Research Institute : DSMB, Executive Committee - Harvard Medical School : Editor, in Chief, Harvard Heart Letter - American College of Cardiology : Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee; JACC Guest Editor; JACC Associate Editor - Duke Clinical Research Institute : Trial Steering Committees and DSMB <p>Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - Elsevier : Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> - Pfizer : Arthritis Clinical Trial Steering Committee - Forest Laboratories : ASCEND COPD CEC Chair - Ischemix : CARIN Chair

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Bhatt Deepak	<p>2018</p> <ul style="list-style-type: none"> - Chiesi Pharma : CHAMPION Trials co-PI - cangrelor - Medicines Company : CHAMPION Trials co-PI - not currently active - cangrelor - Lilly : Clinical Trial Executive Committee - Ironwood : Clinical Trial Planning - Synaptic : Clinical Trial Planning - Bayer : COMPASS Trial Steering Committee, US National Co-Leader, Publications Committee - paid by PHRI - rivaroxaban - Amgen : GOULD Trial Steering Committee - PCSK9 inhibitors - Eisai : LANCELOT Trials co-PI - not currently active - Regeneron : ODYSSEY Outcomes Executive Committee - PCSK9 inhibitor - Sanofi Aventis : ODYSSEY Outcomes Trial Executive Committee - PCSK9 inhibitor; SCORED Trial Chair - sotagliflozin - Amarin : PI of REDUCE IT Trial - icosapent ethyl - Roche Pharma : Planning for clinical trial - not currently active - Boehringer-Ingelheim : REDUAL-PCI Executive Committee - paid by Baim Clinical Research Institute - dabigatran - Bristol Myers Squibb : SAVOR-TIMI 53 Trial co-PI - saxagliptin - Ethicon Endo Surgery GmbH : STAMPEDE Trial co-PI - bariatric surgery - Idorsia : Steering Committee - PhaseBio : Steering Committee Chair - ticagrelor reversal agent - Medtronic : SYMPPLICITY HTN 3 co-PI - renal denervation - Astra Zeneca : THEMIS Trial co-PI - ticagrelor - Abbott Vascular : Xience Short DAPT Trial Executive Committee <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> - Salary paid for by Brigham and Women's Hospital (part of Partners Healthcare System).

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Bhatt Deepak	<p>2018</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care; Chair: American Heart Association Quality Oversight Committee; American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee); Journal of the American College of Cardiology (Guest Editor; Associate Editor); Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair) <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Please find my complete list of disclosures below, largely overlapping with other parts of this form: Dr. Deepak L. Bhatt discloses the following relationships - Advisory Board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, PhaseBio, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Fractyl, Merck, Novo Nordisk, PLx Pharma, Takeda.
	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Tobesoft : Board of Directors

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Bhatt Deepak	<p>2019</p> <ul style="list-style-type: none"> - Medtelligence/ReachMD : CME steering committee - WebMD : CME steering committees, CME programs - Mayo Clinic : DSMB - Cleveland Clinic Research Foundation : DSMB member including for the ExCEED trial, funded by Edwards - Mount Sinai : DSMB, ENVISAGE trial, funded by Daiichi Sankyo - Baim Clinical Research Institute : DSMB, PORTICO trial, funded by St. Jude Medical, now Abbott; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring - HMP Global : Editor in Chief, Journal of Invasive Cardiology - Harvard Medical School : Editor, in Chief, Harvard Heart Letter - MJH Life Sciences : Educational video recordings - Journal of the American College of Cardiology : Guest Editor; Associate Editor - American College of Cardiology : Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee; JACC Guest Editor; JACC Associate Editor - Duke Clinical Research Institute : Trial Steering Committees and DSMB; Steering Committee, PRONOUNCE trial, funded by Ferring Pharmaceuticals - Population Research Institute, McMaster, Hamilton, Canada : Trial Steering Committees, including the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer; DSMBs <p>Receipt of royalties for intellectual property.For yourself</p> <ul style="list-style-type: none"> - Elsevier : Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Pfizer : Arthritis Clinical Trial Steering Committee - Forest Laboratories : ASCEND COPD CEC Chair - Ischemix : CARIN Chair - Chiesi Pharma : CHAMPION Trials co-PI - cangrelor - Medicines Company : CHAMPION Trials co-PI - not currently active - cangrelor

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Bhatt Deepak	<p>2019</p> <ul style="list-style-type: none"> - Lilly : Clinical Trial Executive Committee - Ironwood : Clinical Trial Planning - Synaptic : Clinical Trial Planning - Cardax : Clinical trial planning - Bayer : COMPASS Trial Steering Committee, US National Co-Leader, Publications Committee - paid by PHRI - rivaroxaban - Amgen : GOULD Trial Steering Committee - PCSK9 inhibitors - CSL Behring : Honoraria from Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; AEGIS-II executive committee funded by CSL Behring), - Eisai : LANCELOT Trials co-PI - not currently active - Regeneron : ODYSSEY Outcomes Executive Committee - PCSK9 inhibitor - Sanofi Aventis : ODYSSEY Outcomes Trial Executive Committee - PCSK9 inhibitor; SCORED and Soloist Trial Chair - sotagliflozin - Afimmune : Phase 2 Trial Chair - Amarin : PI of REDUCE IT Trial - icosapent ethyl - Roche Pharma : Planning for clinical trial - not currently active - Boehringer-Ingelheim : REDUAL-PCI Executive Committee - paid by Baim Clinical Research Institute - dabigatran - Bristol Myers Squibb : SAVOR-TIMI 53 Trial co-PI - saxagliptin - Lexicon : SCORED and Soloist Trial Chair - sotagliflozin - Ethicon Endo Surgery GmbH : STAMPEDE Trial co-PI - bariatric surgery - Idorsia : Steering Committee - PhaseBio : Steering Committee Chair - ticagrelor reversal agent - PLx Pharma : Study chair - novel aspirin formulation - Medtronic : SYMPPLICITY HTN 3 co-PI - renal denervation - Astra Zeneca : THEMIS Trial co-PI - ticagrelor - Abbott Vascular : Xience Short DAPT Trial Executive Committee

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Bhatt Deepak	<p>2019</p> <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring. For yourself</p> <ul style="list-style-type: none"> - On staff of Brigham and Women's Hospital, Dana-Farber Cancer Institute, VA Boston Healthcare System <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. For yourself</p> <ul style="list-style-type: none"> - American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee) <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself</p> <ul style="list-style-type: none"> - Please see here for comprehensive listing of disclosures. Dr. Deepak L. Bhatt discloses the following relationships - Advisory Board: Cardax, Cereno Scientific, Elsevier Practice Update Cardiology, Medscape Cardiology, PhaseBio, PLx Pharma, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Novo Nordisk, Takeda.

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<p>2018</p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Apixaban - Astra Zeneca : TICAGRELOR <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : apixaban - Medtronic : COREVALVE
	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : Post-PCI antiplatelet treatment - Bristol Myers Squibb : Post-TAVR antithrombotic treatment <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> - Boston Scientific : Post-TAVR antithrombotic treatment - Bristol Myers Squibb : Post-TAVR antithrombotic treatment
Dendale Paul	<p>2018</p> <p>Financial Declaration</p> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott : CV - Astra Zeneca : cv drugs

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Dendale Paul	2018 <ul style="list-style-type: none"> - Daiichi Sankyo : cv medication - Servier : cv medication - Bristol Myers Squibb : cv medication - Therabel : cv medication - GE Healthcare : echocardio - Biotronik : efo - Medtronic : pm - Boston Scientific : stents
	2019 Financial Declaration Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself <ul style="list-style-type: none"> - Abbott : drugs - Astra Zeneca : drugs - Daiichi Sankyo : drugs - Servier : drugs - Actelion : drugs - Bristol Myers Squibb : drugs - Therabel : drugs - GE Healthcare : echo - Boston Scientific : material - Medtronic : pm
Dorobantu Maria	2018 Nothing to be declared

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Dorobantu Maria	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself - Novo-Nordisk : advisory board - NEOLA PHARMA SRL : advisory board - Sanofi Aventis : honoraria NI - Servier : speaker fee - Bayer : speaker fee ACS - Vifor International : steering committee and NI Travel and meeting support from healthcare industry, independent of the above activities. For yourself - Sanofi Aventis : esc congress - Servier : hypertension congress Receipt of royalties for intellectual property. For yourself - Springer Nature : as co-editor for book "Microcirculation -From Bench to Bedside:
	2018 Nothing to be declared
Edvardsen Thor	2019 Nothing to be declared
	2018 Nothing to be declared

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Folliguet Thierry	2018 Financial Declaration Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry. - Edwards Lifesciences : valves - Llvanova : valves Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry. - Llvanova : honoraria Research funding under your direct/personal responsibility (to department or institution) from healthcare industry. - Llvanova : research clinical nurse
	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself - Llvanova : RCT study Travel and meeting support from healthcare industry, independent of the above activities. For yourself - Edwards Lifesciences : travel fees
Gale Christopher Peter	2018 Financial Declaration Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry. - Astra Zeneca : ACS

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Gale Christopher Peter	2018 <ul style="list-style-type: none"> - Novartis : coronary artery disease - Bayer : coronary artery disease, AF - Vifor International : heart failure - Menarini : ischaemic heart disease <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Apixiban, AF
	2019 <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : ACS - Daiichi Sankyo : AF - Novartis : coronary artery disease - Bayer : coronary artery disease, AF - Vifor International : heart failure - Menarini : ischaemic heart disease <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - BMS : AF - Abbott : Diabetes - National Institute for Health Research : MI - British Heart Foundation : MI, AF - Horizon 2020 : post MI sudden cardiac death

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Gale Christopher Peter	<p>2019</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> - Daiichi Sankyo : AF - Bayer Healthcare : AF, CAD - National Institute for Health and Clinical Excellence : Indicator Advisory Committee <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Apixiban, AF
Gilard Martine	<p>2018</p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : Stent and Valve - Edwards Lifesciences : Stent and valve - Medtronic : Stent and Valve - Abbott Vascular : Stent and Valve <hr/> <p>2019</p> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> - Medtronic : French meetings - Bayer Healthcare : travel to ACC <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> - board of the French Society of Cardiology

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Jobs Alexander	2018 Nothing to be declared
	2019 Nothing to be declared
Juni Peter	2018 Financial Declaration Research funding under your direct/personal responsibility (to department or institution) from healthcare industry. - Astra Zeneca : Anti-platelet Therapy - Biotronik : Drug-eluting stents - Biosensors International Group : Drug-eluting stents - The Medicines Company : Thrombin inhibitors Other Positions of Influence Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Peter Jüni serves as unpaid member of the steering group of trials funded by St. Jude Medical.
	2019 Financial Declaration Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself - Fresenius Nutrition : ECCO2R in COPD - Ava : Fertility App - Amgen Inc : PCSK9 inhibitors in Patients at Cardiovascular Risk

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Juni Peter	<p>2019</p> <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring. For yourself</p> <ul style="list-style-type: none"> - Director, Applied Health Research Centre, St. Michael's Hospital <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself</p> <ul style="list-style-type: none"> - Peter Jüni serves as unpaid member of the steering group of trials funded by Abbott Vascular, Astra Zeneca, Biotronik, Biosensors, St. Jude Medical, Terumo and The Medicines Company, has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly and The Medicines Company, and honoraria to the institution for participation in advisory boards and/or consulting from Amgen, Ava and Fresenius, but has not received personal payments by any pharmaceutical company or device manufacturer.
Lambrinou Ekaterini	<p>2018</p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Health Policy Partnership : HF Policy Network Handbook Launch - Bayer AG : Honorarium - TRAMA SOLUTIONS : Online course speaker fees - Novartis : Speaker fee and honorarium <hr/> <p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For members of your household</p> <ul style="list-style-type: none"> - Novartis : Heart Failure

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Lambrinou Ekaterini	<p>2019</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Novartis : Heart Failure
Lewis Basil S	<p>2018</p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Pfizer : Antithrombotics - Astra Zeneca : Diabetes - Merck Sharp & Dohme : Heart failure - CSL Behring : Lipidology, Secondary prevention <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astrazeneca : Antithrombotics - Astra Zeneca : Diabetes - Pfizer : Diabetes - Merck Sharp & Dohme : Heart failure - Kowa : Lipidology - Resverlogix : Lipidology. secondary prevention <p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Novo-Nordisk : Diabetes

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Lewis Basil S	<p>2019</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : Heart failure - CSL Behring : Lipidology, Secondary prevention <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Pfizer : Diabetes - Merck Sharp & Dohme : Heart failure - Kowa : Lipidology - Resverlogix : Lipidology. secondary prevention
Mehilli Julinda	<p>2018</p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Siemens Healthcare : imaging - Terumo Inc : stents - Boston Scientific : valves - Edwards Lifesciences : valves <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : valves <hr/> <p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Abbott : BVS - Biotronik : BVS

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Mehilli Julinda	<p>2019</p> <ul style="list-style-type: none"> - Astra Zeneca : PCI - Siemens Healthcare : PCI - Bristol Myers Squibb : PCI - Lilly/Daiichi Sankyo : PCI - Terumo Inc : PCI stents - Boston Scientific : structural - TAVI - Edwards Lifesciences : structural TAVI - Medtronic : structural TAVI <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Abbott : BVS - Boston Scientific : structural TAVI - Edwards Lifesciences : structural TAVI
Meliga Emanuele	<p>2018</p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Volcano : iFR / FFR <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> - Medtronic : DES - Amaranth : Renascent - BRS <hr/> <p>2019</p> <p>Nothing to be declared</p>

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Merkely Bela	<p>2018</p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Medtronic : CRT course - Abbott : CRT/ICD - Astra Zeneca : HF - Biotronik : ICD/CRT <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Medtronic : cardiac rhythm management - Boston Scientific : CRT
	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Medtronic : CRT course - Abbott : CRT/ICD - Astra Zeneca : HF - Biotronik : ICD/CRT <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Medtronic : cardiac rhythm management - Boston Scientific : CRT

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Mueller Christian Eugen	<p>2018</p> <p>Financial Declaration</p> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Antidiabetics - Indorsia : Antiplatelet therapy - Roche Diagnostics : Diagnostics - Sanofi Aventis : Lipid lowering - Amgen : Lipid-lowering <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> - Beckman Coulter : Diagnostics - OrthoClinical Diagnostics : Diagnostics - Singulex : Diagnostics - Abbott Laboratories : Diagnostics - Roche Diagnostics : Diagnostics - Siemens : Diagnostics - Sphingotec : Diagnostics - quidel : Diagnostics
	<p>2019</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Bayer : Anticoagulants - Daiichi Sankyo : Anticoagulants - Boehringer-Ingelheim : Antidiabetics

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Mueller Christian Eugen	<p>2019</p> <ul style="list-style-type: none"> - Astra Zeneca : Anti-Diabetics - Idorsia : Antiplatelet therapy - Roche Diagnostics : Diagnostics - Acon : Diagnostics - Novartis : Heart Failure - Sanofi Aventis : Lipid lowering - Amgen : Lipid-lowering <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Novartis : Diagnostics - OrthoClinical Diagnostics : Diagnostics - Abbott Laboratories : Diagnostics - Roche Diagnostics : Diagnostics - Siemens : Diagnostics - Sphingotec : Diagnostics - quidel : Diagnostics
Roffi Marco	<p>2018</p> <p>Financial Declaration</p> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : Stents - Medtronic : Stents - Biotronik : stents - Terumo Inc : stents - Abbott Vascular : stents

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Roffi Marco	<p>2019</p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Boston Scientific : Stents - Medtronic : Stents - Biotronik : stents - GE Healthcare : stents
Rutten Frans Hendrik	<p>2018</p> <p>Financial Declaration</p> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : NOACs, atrial fibrillation - Daiichi Sankyo : NOACs, atrial fibrillation - Pfizer : NOACs, atrial fibrillation - Bayer AG : NOACs, atrial fibrillation <hr/> <p>2019</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Atrial fibrillation - Daiichi Sankyo : Atrial fibrillation - Pfizer : Atrial fibrillation - Bayer Netherlands : Atrial fibrillation

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Sibbing Dirk	<p>2018</p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelets - Sanofi Aventis : Antiplatelets - Roche Diagnostics : Biomarkers in cardiovascular medicine - Bayer Healthcare : NOAC - Daiichi Sankyo : NOACS - Pfizer : NOACS
	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelets - Sanofi Aventis : Antiplatelets - Bayer Healthcare : NOAC - Pfizer : NOACS <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> - Bayer AG : Cardiovascular drugs

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Siontis Georgios	2018 Financial Declaration Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry. - Abbott Vascular : Coronary interventions and intravascular imaging
	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself - Abbott Vascular : Coronary interventions and intravascular imaging
Thiele Holger	2018 Financial Declaration Research funding under your direct/personal responsibility (to department or institution) from healthcare industry. - European Research Foundation FP7 : Cardiogenic shock
	2019 Nothing to be declared

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Aboyans Victor	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Bayer : Antithrombotic therapy - BMS/Pfizer Alliance : Antithrombotic therapy - NovoNordisk : Diabetes - Novartis : Heart Failure - Amgen : Lipid lowering therapy <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> - Bayer Healthcare : Antithrombotic therapy
Addad Faouzi	<p>2019</p> <p>Nothing to be declared</p>
Aidargaliyeva Nazipa	<p>2019</p> <p>Nothing to be declared</p>
Aladashvili Alexander	<p>2019</p> <p>Nothing to be declared</p>
Angiolillo Dominick Joseph	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : Brilinta - Chiesi Pharma : Cangrelor - Daiichi Sankyo : Edoxaban

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Angiolillo Dominick Joseph	<p>2019</p> <ul style="list-style-type: none"> - Pfizer : Eliquis - Bristol Myers Squibb : Eliquis - Amgen : Evolucomab - Biosensors : Freedom stent - NIH : Independent grant- genetics - Sanofi Aventis : Plavix - Boehringer-Ingelheim : Pradaxa - Bayer : Rivaroxaban - Janssen-Cilag : Rivaroxaban - Haemonetics : TEG <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : Brilinta - Chiesi Pharma : cangrelor - Daiichi Sankyo : Edoxaban - Amgen Inc : Evolucomab - Biosensors : Freedom stent - CSL Behring : HDL-raising - Sanofi Aventis : Plavix
Bani Marjeh Mohammed Yassin	<p>2019</p> <p>Nothing to be declared</p>

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Becker David	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Novartis : Heart Failure - Bayer : NOAC - Merck Sharp & Dohme : NOAC <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> - Novartis : Heart Failure
Beigel Roy	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : Cardiovascular - Boehringer-Ingelheim : Cardiovascular - Novartis : Cardiovascular - Pfizer : Cardiovascular - Sanofi Aventis : Cardiovascular - Novo-Nordisk : Cardiovascular
Beishenkulov Medet	<p>2019</p> <p>Nothing to be declared</p>

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Bueno Hector	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Pfizer : Antithrombotics: Apixaban - Bristol Myers Squibb : Antithrombotics: Apixaban - Bayer : Antithrombotics: Aspirin, rivaroxaban - Astra Zeneca : Antithrombotics: Ticagrelor. Heart Failure: Observational studies on use of healthcare resources and economic costs - Novartis : Canakinumab - MEDSCAPE-the heart.org : General (antithrombotics, vaccines) - Amgen : Lipid lowering (PCSK9 inh: alirocumab) <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> - Astrazeneca : Heart Failure <p>Research funding (personal) from healthcare industry. For yourself</p> <ul style="list-style-type: none"> - BMS : CV013-011 - STANDUP-AHF trial - Novartis : LCZ696 (PROMISE trial / PERSPECTIVE trial) Observational study on HF (PREFER Study) - Bayer : New antithrombotics: PACIFIC-MI Trial - Astra Zeneca : Ticagrelor (THEMIS trial). Observational studies (non-drug-related): EPICOR Study on antithrombotics, COHERENT-HF <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. For yourself</p> <ul style="list-style-type: none"> - Vice-president, Spanish Society of Cardiology AHA Fellow Advisor and Scientific Coordinator, Cardiovascular Health Strategy, Ministry of Health, Spain

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Bugiardini Raffaele	2019 Nothing to be declared
Bunc Matjaz	2019 Nothing to be declared
Byrne Robert	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Biotronik : Interventional Cardiology (DES/DCB) - B. Braun : Interventional Cardiology (DES/DCB) Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Celonova Biosciences : Interventional Cardiology (non-DES)
Cassar Andrew J	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Philips : Speaker Fees
Castelletti Silvia	2019 Nothing to be declared
Chettibi Mohamed	2019 Nothing to be declared

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Chieffo Alaide	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Abiomed : high risk PCI <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For members of your household</p> <ul style="list-style-type: none"> - Cordis : coronary - Abbott Vascular : coronary physiology - Biosensors : coronary - Abiomed : high risk PCI <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> - Terumo Inc : travel support for a meeting - Abbott Vascular : travel support for a meeting
Claeys Marc	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Bayer : antithrombotic/antiplatelet - Astra Zeneca : anti-thrombotic/antiplatelet - Sanofi Aventis : lipid disorders - Abbott Vascular/StJude : stents- mitraclip

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Commeau Philippe	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - LS Care : ASD & PFO Device implantation pro wu fitons - Abbott : device - Boston Scientific : device - Edwards Lifesciences : device - Medtronic : device <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. For yourself</p> <ul style="list-style-type: none"> - Healthcare - INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY - Shares (Edwards & GE)
Cornelissen Veronique	<p>2019</p> <p>Nothing to be declared</p>
Crea Filippo	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Oxford University Press : EHJ Honarium - Amgen : Speaker Fee - Astra Zeneca : Speaker Fee - Servier : Speaker fee - Biotronik : Speaker Fee

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Crea Filippo	<p>2019</p> <ul style="list-style-type: none"> - Menarini : Speaker Fee - Bristol Myers Squibb : Speaker Fee <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Biotronik : Phd Research Founding (Direct agreement between Catholic University and Biotronik) <p>Receipt of royalties for intellectual property.For yourself</p> <ul style="list-style-type: none"> - Wolters Kluwer : Royalties - Edra SPA - Masson : Royalties
Damman Peter	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Philips : Intracoronary physiology <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Abbott Vascular : OCT <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : DAPT
Degrell Philippe	<p>2019</p> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> - Terumo Inc : CTO summit - Abbott : LAA closure training

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Delgado Victoria	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - GE Healthcare : 3-dimensional imaging workshop (2000 euro) - Medtronic : aortic stenosis (payment speaker fee 900 euro) - Bayer : diabetes - steering committee (750 euro) - Abbott Vascular : Mitraclip (payment speaker fee 1200 euro) - Edwards Lifesciences : tricuspid valve (payment speaker fee 1200 euro) <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Aortic valve stenosis - Bayer : Heart failure - Bioventrix : heart failure - Abbott Vascular : Mitraclip - Edwards Lifesciences : Tricuspid valve
Drexel Heinz	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Medical University Graz: lecture honoraria : Atherosclerosis - Sanofi: lecture honoraria : Cardiology - MAW: lecture honoraria : Cardiology - Servier: lecture honoraria : Cardiology - ESC: Webinar : Cardiology - Boehringer Ingelheim: consulting activity : Diabetes

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Drexel Heinz	<p>2019</p> <ul style="list-style-type: none"> - Amgen: lecture honoraria : Lipids - MSD: lecture honoraria : Lipids - Medizin Media Austria: consulting activity : Lipids <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Amgen : Lipids - Sanofi Aventis : Lipids
Duplyakov Dmitry	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Sanofi Aventis : Alirocumab - Pfizer : apixaban - Boehringer-Ingelheim : Dabigatran - Berlin Chemie AG : Ranolazine - Bayer Healthcare : Rivaroxaban - Astra Zeneca : Ticagrelor <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : ACCA - Bayer Healthcare : ESC Congress 2019
Elezi Shpend	<p>2019</p> <p>Nothing to be declared</p>
Gaemperli Oliver	<p>2019</p> <p>Nothing to be declared</p>

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Gatzov Plamen Marinov	2019 Nothing to be declared
Gierlotka Marek	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself <ul style="list-style-type: none"> - Bayer : antithrombotic drugs - Boehringer-Ingelheim : drugs - Orion : drugs - Bracco Pharmaceutical : interventional cardiology - Balton : Stents Travel and meeting support from healthcare industry, independent of the above activities. For yourself <ul style="list-style-type: none"> - Astra Zeneca : drugs
Guomundsdottir Ingibjorg Jona	2019 Nothing to be declared
Gustiene Olivija	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself <ul style="list-style-type: none"> - Servier : antihypertensive drugs - Astra Zeneca : antiplatelets, ticagrelor - Sanofi Aventis : PCSK9 inhibitors - Bayer : rivaroxaban - Krka Pharma : statins, antihypertensive

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Gustiene Olivija	<p>2019</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Pfizer : apixaban - Berlin Menarini : Hypertension, infarction, ACEI - Bayer : rivaroxaban - Servier : Stable angina, hypertension <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> - Bayer : ESC congress
Halvorsen Sigrun	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Anticoagulation - Pfizer : Anticoagulation - Bristol Myers Squibb : Anticoagulation - Bayer AS : Anticoagulation - Merck Sharp & Dohme : Glucose lowering drugs - Sanofi Aventis : Lipid lowering treatment
Haugaa Kristina Hermann	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Sanofi Aventis : Cardiogenetics

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Hayrapetyan Hamlet	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Berlin-Chemie Menarini : Arterial Hypertension - Servier : Arterial Hypertension, Coronary Heart Diseases - Egis Pharma : Arterial Hypertension, Coronary Heart Diseases - Bayer : Atrial Fibrillation <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> - Berlin-Chemie Menarini : ACC Congress - Servier : ESC Congress
Hofmann Robin	<p>2019</p> <p>Nothing to be declared</p>
Ibanez Borja	<p>2019</p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : behavioral intervention (no drug) <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself</p> <ul style="list-style-type: none"> - My institution (National Center for Cardiovascular Research, CNIC) is a nonprofit public institution that has royalties for the sales of a polypill (Trinomia) which is constituted by aspirin-ramipril-atorvastatin/simvastatin, but no CNIC researcher has any direct interests (no personal benefits).

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Indolfi Ciro	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Amgen : Cardiovascular - Bayer : Cardiovascular - GE Healthcare : Cardiovascular
Ivanov Victoria	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Krka Pharma : dyslipidemia - Berlin Menarini : frailty patient
Jankowska Ewa Anita	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Bayer : anticoagulants - Astra Zeneca : antiplatelets - Boehringer-Ingelheim : diabetes and CVD - Novartis : Entresto - Abbott : FMR in heart failure - Cardiac Dimensions : heart failure devices - Servier : heart failure, ivabradine - Gedeon Richter : hiperlipidemia

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Jankowska Ewa Anita	<p>2019</p> <ul style="list-style-type: none"> - Fresenius Nutrition : iv iron - Vifor International : IV iron - Berlin Chemie AG : lecanidipine, torasemide <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Vifor International : iv iron <p>Research funding (personal) from healthcare industry.For yourself</p> <ul style="list-style-type: none"> - University of Zurich : heart failure - National Centre for Science (Poland) : iron metabolism, heart failure
Kajander Olli Antero	<p>2019</p> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> - Boston Scientific : Coronary products
Karia Nina	<p>2019</p> <p>Nothing to be declared</p>
Kastrati Adnan	<p>2019</p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> - I am co-inventor of patents related to drug-eluting stent technology; the patent-rights were completely sold in 2018. No royalties have ever been paid.
Katus Hugo	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Anticoagulants

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Katus Hugo	<p>2019</p> <ul style="list-style-type: none"> - Bayer Vital : Anticoagulants - Astrazeneca : Antiplatelet - Novartis : Heart Failure Therapies - Boston Scientific : PCI <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Anticoagulations - Roche Diagnosticsarker : Biomarker
Kedev Sasko	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Meril : Bioresorbable scaffolds - Contego : Carotid artery stenting - Terumo Inc : Radial access; Carotid artery stenting
Kinnaird Tim	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Biosensors : Speaker fees <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Abbott Vascular : Research grant <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> - Abbott Vascular : Meeting sponsorship

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Kluin Jolanda	2019 Nothing to be declared
Kunadian Vijayalakshmi	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself <ul style="list-style-type: none"> - Amgen Inc : Acute coronary syndrome speaker - Daiichi Sankyo : Coronary artery disease speaker - Bayer AG : Digital Steering Committee - Abbott Vascular : Trial Steering Committee member
Kusljugic Zumreta	2019 Nothing to be declared
Landmesser Ulf	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself <ul style="list-style-type: none"> - Abbott : Advisory Board fees - Medicines Company : Advisory Board fees - Bayer : Speaker fee - Amgen : Speaker fees - Sanofi Aventis : Speaker fees Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself <ul style="list-style-type: none"> - Bayer AG : Research Grant

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Leclercq Christophe	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Abbott : devices - Boston Scientific : devices - Medtronic : devices - Biotronik : devices - Microport : devices - Zoll Medical : WCD
Legutko Jacek	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Berlin Menarini : Ezetymib - Bracco Pharmaceutical : HD-IVUS - Philips Volcano : Imaging, IVUS, FFR/iFR - Abbott : Interventional cardiology, electrotherapy (stents, balloons, wires, valves, pacemakers, etc.) - Medtronic : Interventional cardiology, electrotherapy (stents, balloons, wires, valves, pacemakers, etc.) - Balton : Interventional cardiology, electrotherapy (stents, balloons, wires, valves, pacemakers, etc.) - Bayer AG : rivaroxaban - Astra Zeneca : Ticagrelor <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> - Abbott : Interventional cardiology, electrotherapy (stents, balloons, wires, valves, pacemakers, etc.) - Boston Scientific : Interventional cardiology, electrotherapy (stents, balloons, wires, valves, pacemakers, etc.)

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Legutko Jacek	2019 <ul style="list-style-type: none"> - Terumo Inc : Interventional cardiology, electrotherapy (stents, balloons, wires, valves, peacemakers, etc.) - Balton : Interventional cardiology, electrotherapy (stents, balloons, wires, valves, peacemakers, etc.) - Astra Zeneca : Ticagrelor
Lettino Maddalena	2019 <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Bayer : anticoagulants - Daiichi Sankyo : anticoagulants - Pfizer : anticoagulants - Bristol Myers Squibb : anticoagulants - Amgen : lipid-lowering drugs - Sanofi Aventis : lipid-lowering drugs
Maca Aija	2019 <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Bayer : anticoagulation <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> - Bayer : Acute heart failure - Boehringer-Ingelheim : anticoagulation

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Mamas Mamas	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Daiichi Sankyo : antiplatelet managment - Biosensors : bleeding risk - Bayer : digital and e-health <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Medtronic : pacing <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> - ESC Social media lead: unpaid position
Marandi Toomas	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : NA - Sanofi Aventis : NA <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : ESC Congress

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Massberg Steffen	2019 Financial Declaration Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Bristol Myers Squibb : Antithrombotic therapy - Boston Scientific : TAVI
Mates Martin	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Astra Zeneca : speaker fee - Bayer : speaker fee
Meinila Leena	2019 Nothing to be declared
Metzler Bernhard	2019 Nothing to be declared
Morais Joao	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Bayer Portugal : anticoagulants, chronic coronary syndromes Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For members of your household - Astra Zeneca : antiplatelets; acute coronary syndromes; diabetes; anti diabetic drugs - Novartis : heart failure; therapy - Servier : Heart Failure; therapy

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Mylotte Darren	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Biosensors : Coronary Stents - Boston Scientific : TAVI - Medtronic : TAVI - Microport : TAVI <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> - Biosensors : Coronary Stents - Medtronic : TAVI
Najafov Ruslan	<p>2019</p> <p>Nothing to be declared</p>
Ndrepepa Gjin	<p>2019</p> <p>Nothing to be declared</p>
Nikas Dimitrios	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - CSL Behring : Acute Coronary Syndrome - Menarini : Angina - Coronary Artery Disease - Astra Zeneca : Antiplatelet therapy - Sanofi Aventis : Antiplatelet therapy - Boehringer-Ingelheim : NOAC Anticoagulation

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Nikas Dimitrios	<p>2019</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - CSL Behring : Acute Coronary Syndrome - Hypolipidemic therapy <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> - Bayer : Interventional Cardiology Congress <p>Receipt of royalties for intellectual property.For yourself</p> <ul style="list-style-type: none"> - Menarini : Stable Angina
Omerovic Elmir	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Novartis : Acute heart failure - Merck Sharp & Dohme : Acute heart failure <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : Ischemic heart disease
Orban Marek	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Bayer : ACS - Servier : ACS - Zentiva : ACS - Krka Pharma : ACS

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Panayi Georgios	2019 Nothing to be declared
Parkhomenko Alexander	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself <ul style="list-style-type: none"> - Sanofi Aventis : Alirocumab - Amgen : Omecaptive Mecarbil - Bayer Healthcare : rivaroxaban - Astra Zeneca : Ticagrelor, dapagliflozine
Pavlovic Milan	2019 Nothing to be declared
Peace Aaron J	2019 Nothing to be declared
Pedretti Roberto Franco Enrico	2019 Financial Declaration Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself <ul style="list-style-type: none"> - Bristol Myers Squibb : DOACs - Boston Scientific : ICDs
Petersen Steffen Erhard	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself <ul style="list-style-type: none"> - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Petersen Steffen Erhard	<p>2019</p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. For yourself</p> <ul style="list-style-type: none"> - Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.) <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. For yourself</p> <ul style="list-style-type: none"> - Member of the advocacy committee for the Society of Cardiovascular Magnetic Resonance (SCMR).
Petronio Anna Sonia	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Boston Scientific : Structural heart disease - Abbott : structural valve disease <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Medtronic : structural heart disease <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> - Abbott : coronary disease, valve disease - GaDA : valve disease
Pontone Gianluca	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - GE Healthcare : Cardiovascular Imaging - Bracco Pharmaceutical : Cardiovascular Imaging

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Pontone Gianluca	2019 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For members of your household - GlaxoSmithKline : Oncology
Popescu Bogdan Alexandru	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself - GE Healthcare : Imaging Travel and meeting support from healthcare industry, independent of the above activities. For yourself - Bayer : Drug company - antithrombotic drugs
Potpara Tatjana	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself - Pfizer : atrial fibrillation
Ray Kausik K	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself - Novo Nordisk : Diabetes - Boehringer Ingelheim : Diabetes - Astra Zeneca : Diabetes Antiplatelets - Resverlogix : epigenetics - Amgen : lipids - Daiichi Sankyo : Lipids

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Ray Kausik K	<p>2019</p> <ul style="list-style-type: none"> - Medicines Company : Lipids - Kowa : lipids - MSD : lipids - Regeneron : Lipids - Esperion : lipids - Akcea : Lipids - Zuelling Pharma : Lipids - Sanofi Aventis : lipids and Diabetes - Pfizer : lipids Hypertension <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Lipids - Amgen Inc : lipids - Regeneron : lipids
Ribichini Flavio Luciano	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Philips : coronary physiology - Edwards Lifesciences : valvular heart disease - Medtronic : valvular heart disease, hypertension, coronary <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Philips : coronary physiology - Edwards Lifesciences : valvular heart disease

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Richter Dimitrios	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : diabetes - Boehringer-Ingelheim : diabetes - Unipharma : hypertension-thrombosis - Amgen : lipids - Servier : LIPIDS - Sanofi Aventis : Lipids - Lilly : Lipids - Unilever : lipids - Merck Sharp & Dohme : lipids - Vianex : lipids - Mylan : lipids - ELPEN : LIPIDS-THROMBOSIS - Bayer Healthcare : Thrombosis <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> - Amgen : LIPIDS - Bayer : THROMBOSIS
Shlyakhto Evgeny	<p>2019</p> <p>Nothing to be declared</p>
Shokry Khaled	<p>2019</p> <p>Nothing to be declared</p>

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Simpson Iain A	2019 Nothing to be declared
Skoric Bosko	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself - Alvogen : Alvanocyt - Mylan : clopidogrel - Biotest : Cytotect - Sandoz-Novartis : Ferinject - Orion Corporation : Simdax Travel and meeting support from healthcare industry, independent of the above activities. For yourself - Jadran Galenski Laboratorij : ESC congress - Macs Medical : HeartMate Travel and meeting support from healthcare industry, independent of the above activities. For members of your household - Jadran Galenski Laboratorij : ESC congress
Sorensen Rikke	2019 Financial Declaration Travel and meeting support from healthcare industry, independent of the above activities. For yourself - Boehringer-Ingelheim : Participation in ESC Congress 2019
Sousa Uva Miguel	2019 Financial Declaration Travel and meeting support from healthcare industry, independent of the above activities. For yourself - Medtronic : Cardiothoracic Surgery

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Steigen Terje Kristian	2019 Nothing to be declared
Stelmashok Valeriy	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Medtronic : Advisory board fees
Storey Robert	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Thromboserin : Antiplatelet therapy - Astra Zeneca : Antiplatelet therapy, Glucose-lowering therapy - Bayer : Antithrombotic therapy - Portola Pharmaceuticals : Antithrombotic therapy - Bristol Myers Squibb/Pfizer : Antithrombotic therapy - Glycardial Diagnostics : Cardiovascular biomarkers - Medscape : Cardiovascular therapeutics - Haemonetics : Coagulation - Amgen : Lipid lowering Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Thromboserin : Antiplatelet therapy

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Touyz Rhian	<p>2019</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Novartis : Hypertension <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> - I am Editor in Chief of Clinical Science I am Deputy Editor of Hypertension
Tutar Eralp	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : Therapeutic - Menarini : Therapeutic <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> - Medtronic : Meeting support
Valgimigli Marco	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet agents - Daiichi Sankyo : Consultancy -TAVI studies - Terumo Inc : Coronary stent - Abbott Vascular : Coronary Stent

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Valgimigli Marco	<p>2019</p> <ul style="list-style-type: none"> - Alvimedica : coronary stent - Bayer : Oral anticoagulation - Idorsia : Parenteral P2Y12 inhibitor <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Medicure : Antiplatelet agents - Terumo Inc : Coronary stent
Vinereanu Dragos	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : Acute Coronary Syndromes, Diabetes - Boehringer-Ingelheim : Atrial Fibrillation - Pfizer : Atrial Fibrillation - Novartis : Cardiovascular prevention, Heart Failure - Amgen : Heart failure - Servier : Hypertension, Heart Failure <p>Research funding (personal) from healthcare industry.For yourself</p> <ul style="list-style-type: none"> - Johnson & Johnson : Clinical trial - Quintiles : Clinical trial - PPD Global : Clinical trial - Dalcov : Clinical trial - Chiltern : Clinical trial

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Vranckx Pascal	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Daiichi Sankyo : NOAC - Bayer Healthcare : NOAC
Yeh Robert	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : Antithrombotic Therapy - Boston Scientific : Coronary/CTO - Abbott Vascular : Coronary/CTO - Medtronic : Coronary/CTO/PAD <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> - Abbott Vascular : Coronary stents - Astra Zeneca : Heart failure after MI, Diabetes - Boston Scientific : PAD - Medtronic : PAD - Philips : PAD - Bard : PAD - Cook Medical : PAD
Zavatta Marco	<p>2019</p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Aboyans Victor	<p>2018</p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer : Antithrombotic therapy - BMS/Pfizer Alliance : Antithrombotic therapy - NovoNordisk : Diabetes - Novartis : Heart Failure - Amgen : Lipid lowering therapy - Sanofi Aventis : PAD <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer Healthcare : PAD
	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Bayer : Antithrombotic therapy - BMS/Pfizer Alliance : Antithrombotic therapy - NovoNordisk : Diabetes - Novartis : Heart Failure - Amgen : Lipid lowering therapy <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> - Bayer Healthcare : Antithrombotic therapy

ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Baigent Colin	2018 Financial Declaration Research funding under your direct/personal responsibility (to department or institution) from healthcare industry. - Boehringer-Ingelheim : Empagliflozin - Novartis : Sacubitril - Pfizer : Sirolimus
	2019 Financial Declaration Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Boehringer-Ingelheim : Empagliflozin
Collet Jean-Philippe	2018 Financial Declaration Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry. - Bristol Myers Squibb : Apixaban - Astra Zeneca : TICAGRELOR Research funding under your direct/personal responsibility (to department or institution) from healthcare industry. - Bristol Myers Squibb : apixaban - Medtronic : COREVALVE
	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Astra Zeneca : Post-PCI antiplatelet traitement

ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<p>2019</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Post-TAVR antithrombotic treatment <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Boston Scientific : Post-TAVR antithrombotic treatment - Bristol Myers Squibb : Post-TAVR antithrombotic treatment
Delgado Victoria	<p>2018</p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott Vascular : Mitraclip <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> - GE Healthcare : Echocardiography - Edwards Lifesciences : Transcatheter valve interventions <hr/> <p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - GE Healthcare : 3-dimensional imaging workshop (2000 euro) - Medtronic : aortic stenosis (payment speaker fee 900 euro) - Bayer : diabetes - steering committee (750 euro) - Abbott Vascular : Mitraclip (payment speaker fee 1200 euro) - Edwards Lifesciences : tricuspid valve (payment speaker fee 1200 euro) <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Aortic valve stenosis

ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Delgado Victoria	<p>2019</p> <ul style="list-style-type: none"> - Bayer : Heart failure - Bioventrix : heart failure - Abbott Vascular : Mitraclip - Edwards Lifesciences : Tricuspid valve
Fitzsimons Donna	<p>2018</p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Medscape : Heart failure <hr/> <p>2019</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. For yourself</p> <ul style="list-style-type: none"> - Member of Scientific Advisory Board of Northern Ireland Chest Heart & Stroke (Non-Paid)
Gale Christopher Peter	<p>2018</p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : ACS - Novartis : coronary artery disease - Bayer : coronary artery disease, AF - Vifor International : heart failure - Menarini : ischaemic heart disease

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Gale Christopher Peter	2018 Research funding under your direct/personal responsibility (to department or institution) from healthcare industry. - Bristol Myers Squibb : Apixiban, AF
	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself - Astra Zeneca : ACS - Daiichi Sankyo : AF - Novartis : coronary artery disease - Bayer : coronary artery disease, AF - Vifor International : heart failure - Menarini : ischaemic heart disease Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself - BMS : AF - Abbott : Diabetes - National Institute for Health Research : MI - British Heart Foundation : MI, AF - Horizon 2020 : post MI sudden cardiac death Travel and meeting support from healthcare industry, independent of the above activities. For yourself - Daiichi Sankyo : AF - Bayer Healthcare : AF, CAD - National Institute for Health and Clinical Excellence : Indicator Advisory Committee

ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Gale Christopher Peter	2019 Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Bristol Myers Squibb : Apixiban, AF
Grobbee Diederick E	2018 Financial Declaration Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry. - Amgen : advisory board - Esperion : Steering ctt Research funding under your direct/personal responsibility (to department or institution) from healthcare industry. - Esperion : clinical trial lipids Other Positions of Influence Employment in healthcare industry (including part time) during the year for which you are declaring. - chief scientific officer Julius Clinical Research Ltd (part-time)
	2019 Financial Declaration Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Amgen : advisory board - Esperion : Steering ctt Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Esperion : clinical trial lipids

ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Grobbee Diederick E	<p>2019</p> <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring. For yourself</p> <ul style="list-style-type: none"> - Chief Scientific Officer Julius Clinical Academic Contract Research Organization Staff Member, University Medical Center Utrecht
Halvorsen Sigrun	<p>2018</p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Antithrombotic treatment - Astra Zeneca : Anti-thrombotic treatment - Boehringer-Ingelheim : Anti-thrombotic treatment - Pfizer : Anti-thrombotic treatment - Bayer AS : Anti-thrombotic treatment - Sanofi Aventis : Cholesterol lowering treatment <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Novartis : Heart failure
	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Anticoagulation - Pfizer : Anticoagulation - Bristol Myers Squibb : Anticoagulation

ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Halvorsen Sigrun	2019 <ul style="list-style-type: none"> - Bayer AS : Anticoagulation - Merck Sharp & Dohme : Glucose lowering drugs - Sanofi Aventis : Lipid lowering treatment
Hindricks Gerhard	2018 <p>Financial Declaration</p> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott : Pacemaker, Ablation - Biosense Webster : Pacemaker, Ablation - Biotronik : Pacemaker, catheter <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> - Biosense Webster : Electrophysiology, arrhythmias - Abbott : Electrophysiology, arrhythmias <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - The Heart Center Leipzig / University Hospital for Cardiology, Cardiac Surgery and Pediatric Cardiology is part of the Helios Hospital Group. <hr/> 2019 <p>Nothing to be declared</p>

ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Iung Bernard	2018 Financial Declaration Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry. - Boehringer Ingelheim : Anticoagulants - Edwards Lifesciences : Heart valve prostheses
	2019 Financial Declaration Travel and meeting support from healthcare industry, independent of the above activities. For yourself - Abbott : Cardiovascular devices
Juni Peter	2018 Financial Declaration Research funding under your direct/personal responsibility (to department or institution) from healthcare industry. - Astra Zeneca : Anti-platelet Therapy - Biotronik : Drug-eluting stents - Biosensors International Group : Drug-eluting stents - The Medicines Company : Thrombin inhibitors Other Positions of Influence Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Peter Jüni serves as unpaid member of the steering group of trials funded by St. Jude Medical.

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Juni Peter	<p>2019</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Fresenius Nutrition : ECCO2R in COPD - Ava : Fertility App - Amgen Inc : PCSK9 inhibitors in Patients at Cardiovascular Risk <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring. For yourself</p> <ul style="list-style-type: none"> - Director, Applied Health Research Centre, St. Michael's Hospital <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself</p> <ul style="list-style-type: none"> - Peter Jüni serves as unpaid member of the steering group of trials funded by Abbott Vascular, Astra Zeneca, Biotronik, Biosensors, St. Jude Medical, Terumo and The Medicines Company, has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly and The Medicines Company, and honoraria to the institution for participation in advisory boards and/or consulting from Amgen, Ava and Fresenius, but has not received personal payments by any pharmaceutical company or device manufacturer.
Katus Hugo	<p>2018</p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Anticoagulants - Bayer Vital : Anticoagulants - Astrazeneca : Antiplatelet - Roche Diagnostics : Biomar

ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Katus Hugo	<p>2018</p> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> - Roche Diagnosticsarker : Biomarker - Daiichi Sankyo : Xarelto <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - President of the German Society of Cardiology
	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Anticoagulants - Bayer Vital : Anticoagulants - Astrazeneca : Antiplatelet - Novartis : Heart Failure Therapies - Boston Scientific : PCI <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Anticoagulations - Roche Diagnosticsarker : Biomarker
Landmesser Ulf	<p>2018</p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott : Advisory Board fees

ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Landmesser Ulf	<p>2018</p> <ul style="list-style-type: none"> - Medicines Company : Advisory Board fees - Amgen : Speaker fees - Sanofi Aventis : Speaker fees <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer AG : Research Grant
	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Abbott : Advisory Board fees - Medicines Company : Advisory Board fees - Bayer : Speaker fee - Amgen : Speaker fees - Sanofi Aventis : Speaker fees <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> - Bayer AG : Research Grant
Leclercq Christophe	<p>2018</p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott : devices - Boston Scientific : devices - Medtronic : devices - Biotronik : devices

ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Leclercq Christophe	2018 Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry. - Biotronik : devices
	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself - Abbott : devices - Boston Scientific : devices - Medtronic : devices - Biotronik : devices - Microport : devices - Zoll Medical : WCD
Lettino Maddalena	2018 Financial Declaration Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry. - Daiichi Sankyo : Anticoagulants - Pfizer : Anticoagulants - Bayer Healthcare : Antithrombotic agents, anticoagulants - Sanofi Aventis : Antithrombotic agents, anticoagulants, lipid lowering drugs - Astra Zeneca : Antithrombotic agents, statins

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Lettino Maddalena	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Bayer : anticoagulants - Daiichi Sankyo : anticoagulants - Pfizer : anticoagulants - Bristol Myers Squibb : anticoagulants - Amgen : lipid-lowering drugs - Sanofi Aventis : lipid-lowering drugs
Lewis Basil S	<p>2018</p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Pfizer : Antithrombotics - Astra Zeneca : Diabetes - Merck Sharp & Dohme : Heart failure - CSL Behring : Lipidology, Secondary prevention <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astrazeneca : Antithrombotics - Astra Zeneca : Diabetes - Pfizer : Diabetes - Merck Sharp & Dohme : Heart failure

ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Lewis Basil S	2018 <ul style="list-style-type: none"> - Kowa : Lipidology - Resverlogix : Lipidology. secondary prevention
	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself <ul style="list-style-type: none"> - Novo-Nordisk : Diabetes - Merck Sharp & Dohme : Heart failure - CSL Behring : Lipidology, Secondary prevention Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself <ul style="list-style-type: none"> - Pfizer : Diabetes - Merck Sharp & Dohme : Heart failure - Kowa : Lipidology - Resverlogix : Lipidology. secondary prevention
Merkely Bela	2018 Financial Declaration Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry. <ul style="list-style-type: none"> - Medtronic : CRT course - Abbott : CRT/ICD - Astra Zeneca : HF - Biotronik : ICD/CRT

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Merkely Bela	<p>2018</p> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Medtronic : cardiac rhythm management - Boston Scientific : CRT
	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Medtronic : CRT course - Abbott : CRT/ICD - Astra Zeneca : HF - Biotronik : ICD/CRT <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Medtronic : cardiac rhythm management - Boston Scientific : CRT
Mueller Christian Eugen	<p>2018</p> <p>Financial Declaration</p> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Antidiabetics - Indorsia : Antiplatelet therapy - Roche Diagnostics : Diagnostics - Sanofi Aventis : Lipid lowering - Amgen : Lipid-lowering

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Mueller Christian Eugen	<p>2018</p> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> - Beckman Coulter : Diagnostics - OrthoClinical Diagnostics : Diagnostics - Singulex : Diagnostics - Abbott Laboratories : Diagnostics - Roche Diagnostics : Diagnostics - Siemens : Diagnostics - Sphingotec : Diagnostics - quidel : Diagnostics
	<p>2019</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Bayer : Anticoagulants - Daiichi Sankyo : Anticoagulants - Boehringer-Ingelheim : Antidiabetics - Astra Zeneca : Anti-Diabetics - Idorsia : Antiplatelet therapy - Roche Diagnostics : Diagnostics - Acon : Diagnostics - Novartis : Heart Failure - Sanofi Aventis : Lipid lowering - Amgen : Lipid-lowering

ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Mueller Christian Eugen	<p>2019</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Novartis : Diagnostics - OrthoClinical Diagnostics : Diagnostics - Abbott Laboratories : Diagnostics - Roche Diagnostics : Diagnostics - Siemens : Diagnostics - Sphingotec : Diagnostics - quidel : Diagnostics
Petersen Steffen Erhard	<p>2018</p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software - Servier : Heart failure <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - IMAGING - I have option for shares for Circle Cardiovascular Imaging Inc. <hr/> <p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software

ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Petersen Steffen Erhard	<p>2019</p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. For yourself</p> <ul style="list-style-type: none"> - Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.) <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. For yourself</p> <ul style="list-style-type: none"> - Member of the advocacy committee for the Society of Cardiovascular Magnetic Resonance (SCMR).
Petronio Anna Sonia	<p>2018</p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : Percutaneous Aortic and Mitral treatment - Medtronic : Percutaneous Aortic and mitral treatment - Abbott : Percutaneous Mitral treatment <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : TAVI research <hr/> <p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Boston Scientific : Structural heart disease - Abbott : structural valve disease

ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Petronio Anna Sonia	<p>2019</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Medtronic : structural heart disease <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> - Abbott : coronary disease, valve disease - GaDA : valve disease
Priori Silvia Giuliana	<p>2018</p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : Cardiac device <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Audentes Rx : Gene therapy <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> - Takeda Pharmaceuticals : antiarrhythmic drugs <hr/> <p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Boston Scientific : Cardiac Device <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> - Takeda Pharmamaceuticals : Anti-arrhythmic drugs

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Richter Dimitrios	<p>2018</p> <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Edwards Lifesciences : aortic stenosis - Menarini : CAD- hypertension - Unipharma : hypertension-thrombosis - Abbott : lipids - Amgen : lipids - Servier : LIPIDS - Sanofi Aventis : Lipids - Lilly : Lipids - Unilever : lipids - Merck Sharp & Dohme : lipids - Vianex : lipids - RAFARM : LIPIDS - ELPEN : LIPIDS-THROMBOSIS - Bayer Healthcare : Thrombosis - Leo Pharma : THROMBOSIS - NovaGEM CYPRUS : THROMBOSIS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Richter Dimitrios	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Astra Zeneca : diabetes - Boehringer-Ingelheim : diabetes - Unipharma : hypertension-thrombosis - Amgen : lipids - Servier : LIPIDS - Sanofi Aventis : Lipids - Lilly : Lipids - Unilever : lipids - Merck Sharp & Dohme : lipids - Vianex : lipids - Mylan : lipids - ELPEN : LIPIDS-THROMBOSIS - Bayer Healthcare : Thrombosis <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself</p> <ul style="list-style-type: none"> - Amgen : LIPIDS - Bayer : THROMBOSIS
Roffi Marco	<p>2018</p> <p>Financial Declaration</p> <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : Stents

ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Roffi Marco	2018 <ul style="list-style-type: none"> - Medtronic : Stents - Biotronik : stents - Terumo Inc : stents - Abbott Vascular : stents
	2019 <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Boston Scientific : Stents - Medtronic : Stents - Biotronik : stents - GE Healthcare : stents
Shlyakhto Evgeny	2018 <p>Financial Declaration</p> <p>Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Krka Pharma : Arterial Hypertension - Novartis : Arterial Hypertension, Heart Failure - Merck Sharp & Dohme : Atherosclerosis - Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation - Pfizer : General Cardiology
	2019 <p>Nothing to be declared</p>
Simpson Iain A	2018 <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Simpson Iain A	2019 Nothing to be declared
Sousa Uva Miguel	2018 Financial Declaration Direct personal payment as it applies to you and your spouse/partner or any other member of your household, or any entity controlled directly or indirectly by any of above persons: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry. - Abott : Surgical Valves
	2019 Financial Declaration Travel and meeting support from healthcare industry, independent of the above activities. For yourself - Medtronic : Cardiothoracic Surgery
Touyz Rhian	2018 Financial Declaration Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry. - Novartis : antihypertensive drugs - Alnylam : antihypertensive drugs Research funding (personal). - British Heart Foundation : Hypertension research - Medical Research Council, UK : Hypertension research Other Positions of Influence Membership or affiliation in political or advocacy groups working in the field of cardiology. - American Heart Association International Society of Hypertension British Irish Hypertension Society

ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Touyz Rhian	<p>2019</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> - Novartis : Hypertension <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself</p> <ul style="list-style-type: none"> - I am Editor in Chief of Clinical Science I am Deputy Editor of Hypertension
Windecker Stephan	<p>2018</p> <p>Financial Declaration</p> <p>Payment to your department or institution or any other body like an association or similar for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - CSL Behring : Invasive Cardiology - Polares Medical : Invasive Cardiology <p>Research funding under your direct/personal responsibility (to department or institution) from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott : General Cardiology - Boston Scientific : General Cardiology - Edwards Lifesciences : General Cardiology - Medtronic : General Cardiology - Biotronik : General Cardiology - Amgen Inc : General Cardiology - Bristol Myers Squibb : General Cardiology - Bayer AG : General Cardiology - Sinomed : General Cardiology

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Windecker Stephan	<p>2018</p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Deputy Editor JACC CV Interventions Section Editor Uptodate Board Member SITEM (Swiss Institute of Translational and Entrepreneur Medicine) Advisor ECRI (European Cardiovascular Research Institute) Course Director, PCR
	<p>2019</p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Anticoagulation - Amgen : Dyslipidemia - Johnson & Johnson : Electrophysiology and General Cardiology - Daiichi Sankyo : General Cardiology - Terumo Inc : General Cardiology - Sanofi Aventis : General Cardiology - Bayer AG : General Cardiology - CSL Behring : General Cardiology - Cardinal health : General Cardiology - Guerbet AG : General Cardiology - Abbott : Invasive Cardiology - Boston Scientific : Invasive Cardiology - Edwards Lifesciences : Invasive Cardiology - Medtronic : Invasive Cardiology and Electrophysiology - Biotronik : Invasive Cardiology and Electrophysiology

ESC Committee for Practice Guidelines 2018-2020

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2019.

Expert	Type of Relationship with Industry
Windecker Stephan	<p>2019</p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself - Deputy Editor JACC CV Intervention , Section Editor Uptodate, Course Director PCR</p>